Welcome to GenPrice! Check out our latest updates.

Shopping Cart (0)

Your cart is empty

Add some products to get started!

Elacestrant (dihydrochloride)

Elacestrant (RAD1901) dihydrochloride is an orally available and selective estrogen receptor degrader (SERD) with IC50s of 48 and 870 nM for ERα and ERβ, respectively. Elacestrant dihydrochloride also can inhibit growth of ER+ breast cancer cell lines in vitro and in vivo[1][2].

Product Specifications

CAS Number

1349723-93-8

Product Name Alternative

RAD1901 dihydrochloride

UNSPSC

12352005

Target

Estrogen Receptor/ERR

Type

Reference compound

Related Pathways

Vitamin D Related/Nuclear Receptor

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/Elacestrant__dihydrochloride_.html

Purity

99.54

Solubility

DMSO : 100 mg/mL (ultrasonic) |H2O : 50 mg/mL (ultrasonic)

Smiles

OC1=CC=C2C[C@H](C3=CC=C(OC)C=C3N(CC)CC4=CC=C(CCNCC)C=C4)CCC2=C1.[H]Cl.[H]Cl

Molecular Formula

C30H40Cl2N2O2

Molecular Weight

531.56

References & Citations

[1]Garner F, et al. RAD1901: a novel, orally bioavailable selective estrogen receptor degrader that demonstrates antitumor activity in breast cancer xenograft models. Anticancer Drugs. 2015 Oct;26 (9) :948-56.|[2]Bihani T, et al. Elacestrant (RAD1901), a Selective Estrogen Receptor Degrader (SERD), Has Antitumor Activity in Multiple ER+ Breast Cancer Patient-derived Xenograft Models. Clin Cancer Res. 2017 Aug 15;23 (16) :4793-4804.

Shipping Conditions

Room Temperature

Storage Conditions

4°C (Powder, sealed storage, away from moisture)

Scientific Category

Reference compound1

Clinical Information

Launched

Citation 01

Cancer Discov. 2024 Feb 8;14 (2) :274-289.|Cancer Res. 2024 Dec 16;84 (24) :4283-4297.|J Med Chem. 2020 Oct 8;63 (19) :11085-11099.|Mol Cancer Ther. 2020 Jul;19 (7) :1395-1405.|Biomed Pharmacother. 2024 Nov:180:117523.|bioRxiv. 2023 Nov 2.|bioRxiv. 2024 Jun 2:2024.05.28.596307.|bioRxiv. 2025 Nov 21:2025.11.20.689560.|Genes Dev. 2025 Nov 5.|Harvard University. 2023 Mar. 30487357.|J Cell Mol Med. 2023 Sep;27 (17) :2467-2481.|NPJ Breast Cancer. 2022 Dec 14;8 (1) :130.|NPJ Breast Cancer. 2025 Nov 12;11 (1) :125.|Res Sq. 2024 Jun 04.|Research Square Preprint. 2023 May 9.|Research Square Preprint. 2024 Nov 06.

Available Sizes

Frequently Asked Questions

More Discoveries

Explore Other Products

Browse additional items from our catalog

Armcx2 Mouse Gene Knockout Kit (CRISPR)
KN501598 1 Kit

Armcx2 Mouse Gene Knockout Kit (CRISPR)

Sign In for Pricing
View Details
Complement C7 (C7) Goat Polyclonal Antibody
AP32959PU-N 100 µg

Complement C7 (C7) Goat Polyclonal Antibody

Sign In for Pricing
View Details
SLITL2 (VASN) Rabbit Polyclonal Antibody
TA383197 100 µL

SLITL2 (VASN) Rabbit Polyclonal Antibody

Sign In for Pricing
View Details
Prostate Specific Antigen (PSA) (KLK3/2871R), CF405S conjugate, 0.1mg/mL
BNC042871-500 1x 500 µL

Prostate Specific Antigen (PSA) (KLK3/2871R), CF405S conjugate, 0.1mg/mL

Sign In for Pricing
View Details
CETP (NM_000078) Human Over-expression Lysate
LC424935 20 µg

CETP (NM_000078) Human Over-expression Lysate

Sign In for Pricing
View Details
Human C17orf46 (SPATA32) activation kit by CRISPRa
GA114859 1 Kit

Human C17orf46 (SPATA32) activation kit by CRISPRa

Sign In for Pricing
View Details